Vertex Pharmaceuticals Inc
Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –
Vertex Pharmaceuticals Non-GAAP combined R&D, AIPR&D and SG&A expenses by Quarter
Non-GAAP combined R&D, AIPR&D and SG&A expenses ($M) ($M)
Vertex Pharmaceuticals Non-GAAP combined R&D, AIPR&D and SG&A expenses: $1,430M in Q2 2026, up 15.4% from a year earlier.
Where the Q2 2026 figure comes from
“|| Combined non-GAAP R&D, AIPR&D and SG&A expenses | $ | 1,430.3 | $ | 1,239.7 | $ | 2,722.3 | $ | 2,471.5”
Source: Form 8-K (ex-991_q22026.htm, filed 2026-08-03) ↗
Reported in Form 8-K EX-99.1 Earnings Releases (GAAP to Non-GAAP Reconciliations).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up non-GAAP combined R&D, AIPR&D and SG&A expenses
Cite this data
StockData. (2026). Vertex Pharmaceuticals Non-GAAP combined R&D, AIPR&D and SG&A expenses ($M), quarterly Q4 2016–Q2 2026 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/nongaap-comb-rd-sga
See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.